IllnessPeritoneal carcinoma / PARP inhibitor therapy

Request form illness

Order shipping materials

Summary

Short information

Comprehensive panel to decide on PARP inhibitor therapy for Peritoneal cancer comprising 2 guideline-curated genes

OP1005

Number of genes

2 Accredited laboratory test

Examined sequence length

15,9 kb (Core-/Core-canditate-Genes)
- (Extended panel: incl. additional genes)

Analysis Duration

on request

Test material

EDTA-anticoagulated blood (3-5 ml)
Gewebeprobe

Diagnostic indications

NGS +

SANGER

Gene panel

Selected genes

Name	Exon Length (bp)	OMIM-G	Referenz-Seq.	Heredity
BRCA1	5592	113705	NM_007294.4	-
BRCA2	10257	600185	NM_000059.4	AD

Informations about the disease

Clinical Comment

The PARP inhibitor olaparib is approved as a monotherapy for the maintenance treatment of primary peritoneal carcinoma that has previously responded sensitively to platinum-based chemotherapy (1, 2). Olaparib capsules are only used if a mutation in the BRCA1 or BRCA2 genes has previously been detected in the germ line or tumor in the patient concerned (3). Olaparib treatment provides longer progression-free survival.

References: (1) https://www.dgho.de/publikationen/stellungnahmen/fruehe-nutzenbewertung/olaparib/olaparib-mammakarzinom-stellungnahme-20191105.pdf (2) https://pubmed.ncbi.nlm.nih.gov/28754483/ (3) https://www.kvn.de/internet_media/Mitglieder/Praxisf%C3%BChrung/Publikationen/Rundschreiben/Rundschreiben+2019.pdf

Synonyms

Alias: Olaparib-Therapie (BRCA1, BRCA2)
Alias: Peritoneal-Ca, Behandlung mit PARP-Inhibitoren (BRCA1, BRCA2)
Peritoneum carcinoma (BRCA1, BRCA2) - Olaparib therapy

Heredity, heredity patterns etc.

OMIM-Ps

No OMIM-Ps linked

ICD10 Code

Bioinformatics and clinical interpretation

No text defined